161 related articles for article (PubMed ID: 32687165)
41. KDM6A-Mediated Expression of the Long Noncoding RNA DINO Causes TP53 Tumor Suppressor Stabilization in Human Papillomavirus 16 E7-Expressing Cells.
Sharma S; Munger K
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269126
[TBL] [Abstract][Full Text] [Related]
42. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation.
Santos L; Mention K; Cavusoglu-Doran K; Sanz DJ; Bacalhau M; Lopes-Pacheco M; Harrison PT; Farinha CM
J Cyst Fibros; 2022 Jan; 21(1):181-187. PubMed ID: 34103250
[TBL] [Abstract][Full Text] [Related]
43. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review).
Rodríguez-Rodríguez DR; Ramírez-Solís R; Garza-Elizondo MA; Garza-Rodríguez ML; Barrera-Saldaña HA
Int J Mol Med; 2019 Apr; 43(4):1559-1574. PubMed ID: 30816503
[TBL] [Abstract][Full Text] [Related]
44. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
Schwermer M; Hiber M; Dreesmann S; Rieb A; Theißen J; Herold T; Schramm A; Temming P; Steenpass L
Exp Cell Res; 2019 Feb; 375(2):92-99. PubMed ID: 30584916
[TBL] [Abstract][Full Text] [Related]
46. Generation of NERCe003-A-3, a p53 compound heterozygous mutation human embryonic stem cell line, by CRISPR/Cas9 editing.
Li Y; Huang C; Zha L; Kong M; Yang Q; Zhu Y; Peng Y; Ouyang Q; Lu G; Lin G; Zhou D
Stem Cell Res; 2019 Jan; 34():101371. PubMed ID: 30658254
[TBL] [Abstract][Full Text] [Related]
47. Pan-Cancer Molecular Patterns and Biological Implications Associated with a Tumor-Specific Molecular Signature.
Rocha D; García IA; González Montoro A; Llera A; Prato L; Girotti MR; Soria G; Fernández EA
Cells; 2020 Dec; 10(1):. PubMed ID: 33396205
[TBL] [Abstract][Full Text] [Related]
48. SpRY Cas9 Can Utilize a Variety of Protospacer Adjacent Motif Site Sequences To Edit the Candida albicans Genome.
Evans BA; Bernstein DA
mSphere; 2021 May; 6(3):. PubMed ID: 34011687
[No Abstract] [Full Text] [Related]
49. Recruitment of DNA Repair MRN Complex by Intrinsically Disordered Protein Domain Fused to Cas9 Improves Efficiency of CRISPR-Mediated Genome Editing.
Reuven N; Adler J; Broennimann K; Myers N; Shaul Y
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31597252
[TBL] [Abstract][Full Text] [Related]
50. Enhancing site-specific DNA integration by a Cas9 nuclease fused with a DNA donor-binding domain.
Ma S; Wang X; Hu Y; Lv J; Liu C; Liao K; Guo X; Wang D; Lin Y; Rong Z
Nucleic Acids Res; 2020 Oct; 48(18):10590-10601. PubMed ID: 32986839
[TBL] [Abstract][Full Text] [Related]
51. Manipulating plant RNA-silencing pathways to improve the gene editing efficiency of CRISPR/Cas9 systems.
Mao Y; Yang X; Zhou Y; Zhang Z; Botella JR; Zhu JK
Genome Biol; 2018 Sep; 19(1):149. PubMed ID: 30266091
[TBL] [Abstract][Full Text] [Related]
52. Temperature effect on CRISPR-Cas9 mediated genome editing.
Xiang G; Zhang X; An C; Cheng C; Wang H
J Genet Genomics; 2017 Apr; 44(4):199-205. PubMed ID: 28412228
[TBL] [Abstract][Full Text] [Related]
53. Sharpening the Scissors: Mechanistic Details of CRISPR/Cas9 Improve Functional Understanding and Inspire Future Research.
Raper AT; Stephenson AA; Suo Z
J Am Chem Soc; 2018 Sep; 140(36):11142-11152. PubMed ID: 30160947
[TBL] [Abstract][Full Text] [Related]
54. Single-Strand Annealing Plays a Major Role in Double-Strand DNA Break Repair following CRISPR-Cas9 Cleavage in
Zhang WW; Matlashewski G
mSphere; 2019 Aug; 4(4):. PubMed ID: 31434745
[TBL] [Abstract][Full Text] [Related]
55. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in
Stolte B; Iniguez AB; Dharia NV; Robichaud AL; Conway AS; Morgan AM; Alexe G; Schauer NJ; Liu X; Bird GH; Tsherniak A; Vazquez F; Buhrlage SJ; Walensky LD; Stegmaier K
J Exp Med; 2018 Aug; 215(8):2137-2155. PubMed ID: 30045945
[TBL] [Abstract][Full Text] [Related]
56. CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions.
Su D; Feng X; Colic M; Wang Y; Zhang C; Wang C; Tang M; Hart T; Chen J
DNA Repair (Amst); 2020 Mar; 87():102803. PubMed ID: 31991288
[TBL] [Abstract][Full Text] [Related]
57. TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening.
Álvarez MM; Biayna J; Supek F
Nat Commun; 2022 Aug; 13(1):4520. PubMed ID: 35927263
[TBL] [Abstract][Full Text] [Related]
58. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing.
Leibowitz ML; Papathanasiou S; Doerfler PA; Blaine LJ; Sun L; Yao Y; Zhang CZ; Weiss MJ; Pellman D
Nat Genet; 2021 Jun; 53(6):895-905. PubMed ID: 33846636
[TBL] [Abstract][Full Text] [Related]
59. Speed genome editing by transient CRISPR/Cas9 targeting and large DNA fragment deletion.
Luo J; Lu L; Gu Y; Huang R; Gui L; Li S; Qi X; Zheng W; Chao T; Zheng Q; Liang Y; Zhang L
J Biotechnol; 2018 Sep; 281():11-20. PubMed ID: 29886029
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing.
Liu B; Chen S; Rose A; Chen D; Cao F; Zwinderman M; Kiemel D; Aïssi M; Dekker FJ; Haisma HJ
Nucleic Acids Res; 2020 Jan; 48(2):517-532. PubMed ID: 31799598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
